These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12386001)

  • 21. Distinct Protein Expression Profiles of Solid-Pseudopapillary Neoplasms of the Pancreas.
    Park M; Lim JS; Lee HJ; Na K; Lee MJ; Kang CM; Paik YK; Kim H
    J Proteome Res; 2015 Aug; 14(8):3007-14. PubMed ID: 26148796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins.
    Chen Y; Fisher KJ; Lloyd M; Wood ER; Coppola D; Siegel E; Shibata D; Chen YA; Koomen JM
    Methods Mol Biol; 2017; 1647():19-45. PubMed ID: 28808993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and Validation of Biomarkers That Distinguish Mucinous and Nonmucinous Pancreatic Cysts.
    Park J; Yun HS; Lee KH; Lee KT; Lee JK; Lee SY
    Cancer Res; 2015 Aug; 75(16):3227-35. PubMed ID: 26122842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets.
    Mayburd AL; Golovchikova I; Mulshine JL
    Bioinformatics; 2008 Feb; 24(3):389-95. PubMed ID: 17925305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absolute quantitation of protein posttranslational modification isoform.
    Yang Z; Li N
    Methods Mol Biol; 2015; 1306():105-19. PubMed ID: 25930697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isotope-differentiated binding energy shift tags (IDBEST) for improved targeted biomarker discovery and validation.
    Hall MP; Schneider LV
    Expert Rev Proteomics; 2004 Dec; 1(4):421-31. PubMed ID: 15966839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma.
    Lai X; Chen S
    Cancer Genomics Proteomics; 2015; 12(6):271-81. PubMed ID: 26543076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global MS-Based Proteomics Drug Profiling.
    Carvalho AS; Matthiesen R
    Methods Mol Biol; 2016; 1449():469-79. PubMed ID: 27613057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction.
    Ortea I; Rodríguez-Ariza A; Chicano-Gálvez E; Arenas Vacas MS; Jurado Gámez B
    J Proteomics; 2016 Apr; 138():106-14. PubMed ID: 26917472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry.
    Yu KH; Rustgi AK; Blair IA
    J Proteome Res; 2005; 4(5):1742-51. PubMed ID: 16212428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential protein expression and peak selection in mass spectrometry data by binary discriminant analysis.
    Gibb S; Strimmer K
    Bioinformatics; 2015 Oct; 31(19):3156-62. PubMed ID: 26026136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inverse 15N-metabolic labeling/mass spectrometry for comparative proteomics and rapid identification of protein markers/targets.
    Wang YK; Ma Z; Quinn DF; Fu EW
    Rapid Commun Mass Spectrom; 2002; 16(14):1389-97. PubMed ID: 12112619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in clinical proteomics using mass spectrometry.
    Dowling P; Meleady P; Henry M; Clynes M
    Bioanalysis; 2010 Sep; 2(9):1609-15. PubMed ID: 21083289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomics approaches for myeloid leukemia drug discovery.
    Kapoor I; Pal P; Lochab S; Kanaujiya JK; Trivedi AK
    Expert Opin Drug Discov; 2012 Dec; 7(12):1165-75. PubMed ID: 22971110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer.
    Ueda K; Katagiri T; Shimada T; Irie S; Sato TA; Nakamura Y; Daigo Y
    J Proteome Res; 2007 Sep; 6(9):3475-83. PubMed ID: 17705522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomics-based identification of tumor relevant proteins in lung adenocarcinoma.
    Zhou X; Xue L; Hao L; Liu S; Zhou F; Xiong H; Qi X; Lin D; Shao S
    Biomed Pharmacother; 2013 Sep; 67(7):621-7. PubMed ID: 23916545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.
    Qiu JX; Zhou ZW; He ZX; Zhao RJ; Zhang X; Yang L; Zhou SF; Mao ZF
    Drug Des Devel Ther; 2015; 9():349-417. PubMed ID: 25609920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomic Approaches for Biomarker Panels in Cancer.
    Tanase C; Albulescu R; Neagu M
    J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A simple peak detection and label-free quantitation algorithm for chromatography-mass spectrometry.
    Aoshima K; Takahashi K; Ikawa M; Kimura T; Fukuda M; Tanaka S; Parry HE; Fujita Y; Yoshizawa AC; Utsunomiya S; Kajihara S; Tanaka K; Oda Y
    BMC Bioinformatics; 2014 Nov; 15(1):376. PubMed ID: 25420746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.